Forward Progress: ESG Primer on Clinical Trial Diversity
Insight by Eric Assaraf, Rick Weissenstein, John Miller, Joshua Jennings, Ken Cacciatore, Daniel Brennan, Ritu Baral, Max Masucci, Phil Nadeau, Boris Peaker, Charles Rhyee, Steve Scala, Joseph Thome, Tyler Van Buren and Yaron Werber
In this multi-analyst, multi-industry report, Cowen Research provides the first of its kind analysis of the current state of clinical trial diversity. There’s accelerating ESG investor interest in clinical trial diversity as a metric of a medical product company’s commitment to access within the Social element of ESG. We seek to provide:
- a robust assessment of the current state of clinical trial representation
- the nuances of different technologies and diseases
- an understanding of the steps companies are taking
- insight into where areas of progress are sorely lacking
This report focuses on diseases that disproportionately affect certain racial, ethnic, sexual identity, or gender subgroups, as well as an assessment of the steps companies are taking to improve trial diversity. We also spoke with several KOLs, including regulatory and CRO experts as well as KOLs that work with minority groups to improve access to and representation in clinical studies.
By clicking above, I agree that Cowen may use and store the personal information I provide to interact with me. See also https://cowen.com/privacy
Get the Full Report
If you’re already a member of our Research portal, log in.
Log InIf not, reach out to us directly for more information.